Cogent Biosciences Inc
$ 39.31
0.38%
04 Dec - close price
- Market Cap 6,034,304,000 USD
- Current Price $ 39.31
- High / Low $ 39.58 / 37.94
- Stock P/E N/A
- Book Value 1.39
- EPS -2.05
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.48 %
- ROE -0.95 %
- 52 Week High 41.27
- 52 Week Low 3.72
About
Cogent Biosciences, Inc. is a pioneering biotechnology firm based in Cambridge, Massachusetts, dedicated to the development of precision therapies for genetically defined diseases. Leveraging its proprietary platform, the company targets specific genetic mutations to create tailored therapeutic solutions that promise to enhance patient outcomes significantly. With a strong pipeline of innovative treatments and a clear focus on transforming the landscape of precision medicine, Cogent is positioned as a compelling investment opportunity for institutional investors seeking robust growth in the advanced biopharmaceuticals sector.
Analyst Target Price
$47.18
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-17 | 2025-08-05 | 2025-05-05 | 2025-02-24 | 2024-10-31 | 2024-08-06 | 2024-05-07 | 2024-02-26 | 2023-11-02 | 2023-08-08 | 2023-05-09 | 2023-03-14 |
| Reported EPS | -0.5 | -0.595 | -0.5249 | -0.09 | -0.6412 | -0.59 | -0.62 | -0.63 | -0.64 | -0.59 | -0.54 | -0.56 |
| Estimated EPS | -0.5229 | -0.5867 | -0.5771 | -0.5837 | -0.5664 | -0.56 | -0.52 | -0.56 | -0.5 | -0.54 | -0.57 | -0.52 |
| Surprise | 0.0229 | -0.0083 | 0.0522 | 0.4937 | -0.0748 | -0.03 | -0.1 | -0.07 | -0.14 | -0.05 | 0.03 | -0.04 |
| Surprise Percentage | 4.3794% | -1.4147% | 9.0452% | 84.5811% | -13.2062% | -5.3571% | -19.2308% | -12.5% | -28% | -9.2593% | 5.2632% | -7.6923% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: COGT
2025-11-19 09:06:44
Cogent Biosciences (COGT) has completed a $230 million offering of Convertible Senior Notes due 2031 to strengthen its capital structure and enhance market position. TipRanks’ AI Analyst, Spark, rates COGT as Underperform due to significant financial difficulties, ongoing operating losses, and an unattractive valuation. The company focuses on developing precision therapies for rare genetic disorders and cancer.
2025-11-18 11:06:44
Profund Advisors LLC reduced its stake in Cogent Biosciences, Inc. by 42.2% in the second quarter, now holding 20,157 shares valued at $145,000. Several other institutional investors also adjusted their positions in COGT, while analysts have issued a "Moderate Buy" consensus with an average target price of $32.33. The company recently reported better-than-expected quarterly EPS of ($0.50).
2025-11-17 09:06:45
Candriam S.C.A. acquired a new stake of 427,342 shares in Cogent Biosciences, Inc. (NASDAQ:COGT) valued at approximately $3.07 million during the second quarter, representing about 0.38% of the company. Other institutional investors also adjusted their positions in COGT. Cogent Biosciences reported Q2 EPS of -$0.50, beating estimates, and analysts have a "Moderate Buy" rating with an average target price of $32.33, with some firms raising targets significantly.
2025-11-14 08:00:00
Cogent Biosciences, Inc. announced its participation in the Jefferies Global Healthcare Conference in London on November 19, 2025. The company will present at 11:30 a.m. GMT (6:30 a.m. ET), and a live webcast will be available on their Investors & Media page. Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, with its lead clinical program, bezuclastinib, targeting the KIT D816V mutation for systemic mastocytosis and GIST.
2025-11-12 09:06:45
Cogent Biosciences announced proposed concurrent public offerings of $200 million in convertible senior notes due 2031 and $200 million in common stock. The company plans to use the net proceeds to repay an existing term loan and fund development, regulatory activities, and commercialization of its product candidates, including bezuclastinib. Jefferies and J.P. Morgan are lead managers for the offerings, which are subject to market conditions.
2025-10-16 02:45:11
Stifel has initiated coverage on Cogent stock with a "Hold" rating and a price target of $16. The article indicates that there was an application error preventing the full content from loading.
